Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • News & Views
  • Published:

Direct-acting antivirals for paediatric HCV: we got there

Nature Reviews Gastroenterology & Hepatology volume 14, pages 452–453 (2017)Cite this article

Subjects

In a new report, adolescents with genotype 2 or 3 HCV infection who were given sofosbuvir and ribavirin showed a near 100% sustained virologic response. This study is the beginning of a new wave of treatments for paediatric HCV infection, forming part of a global strategy to eradicate viral hepatitis.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. Wirth, S. et al. Sofosbuvir and ribavirin in adolescents 12 to 17 years old with hepatitis C virus genotype 2 or 3 infection. Hepatology http://dx.doi.org/10.1002/hep.29278 (2017).

  2. US Food & Drug Administration. Highlights of prescribing information for SOVALDI® (sofosbuvir) tablets, for oral use. US FDA https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/204671s006lbl.pdf (updated Mar 2017).

  3. Wirth, S. Current treatment options and response rates in children with chronic hepatitis C. World J. Gastroenterol. 18, 99–104 (2012).

    Article  CAS  Google Scholar 

  4. Jacobson, K. R., Murray, K., Zellos, A. & Schwarz, K. B. An analysis of published trials of interferon monotherapy in children with chronic hepatitis C. J. Pediatr. Gastroenterol. Nutr. 34, 52–58 (2002).

  5. Pawlotsky, J. M., Feld, J. J., Zeuzem, S. & Hoofnagle, J. H. From non-A, non-B hepatitis to hepatitis C virus cure. J. Hepatol. 62 (Suppl. 1), S87–S99 (2015).

    Article  CAS  Google Scholar 

  6. European Medicines Agency. Summary of product characteristics. EMA http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000281/WC500034679.pdf (updated 9 Mar 2017).

  7. Druyts, E. et al. Efficacy and safety of pegylated interferon α-2a or α-2b plus ribavirin for the treatment of chronic hepatitis C in children and adolescents: a systematic review and meta-analysis. Clin. Infect. Dis. 56, 961–967 (2013).

    Article  CAS  Google Scholar 

  8. World Health Organization. Global hepatitis report (WHO, 2017).

  9. European Association for the Study of the Liver. EASL recommendations on treatment of hepatitis C 2016. J. Hepatol. 66, 153–194 (2017).

  10. Bortolotti, F. et al. Long-term course of chronic hepatitis C in children: from viral clearance to end-stage liver disease. Gastroenterol. 134, 1900–1907 (2008).

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Etienne M. Sokal is at the Université catholique de Louvain, Cliniques Universitaires Saint-Luc, 10 Avenue Hippocrate, Brussels, B-1200, Belgium

    Etienne M. Sokal

Authors
  1. Etienne M. Sokal
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Etienne M. Sokal.

Ethics declarations

Competing interests

E.M.S. is an investigator for Abbvie, Gilead, Johnson & Johnson and a consultant for Abbvie.

Related links

FURTHER INFORMATION

ClinicalTrials.gov

PowerPoint slides

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Sokal, E. Direct-acting antivirals for paediatric HCV: we got there. Nat Rev Gastroenterol Hepatol 14, 452–453 (2017). https://doi.org/10.1038/nrgastro.2017.92

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrgastro.2017.92

This article is cited by

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing